Sunshine Biopharma, Inc.
SBFM
$1.59
-$0.11-6.47%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 8.90M | 9.60M | 8.44M | 9.30M | 7.54M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 8.90M | 9.60M | 8.44M | 9.30M | 7.54M |
| Cost of Revenue | 6.17M | 6.50M | 5.57M | 6.95M | 5.19M |
| Gross Profit | 2.73M | 3.09M | 2.87M | 2.36M | 2.35M |
| SG&A Expenses | 3.64M | 4.81M | 3.73M | 2.99M | 3.36M |
| Depreciation & Amortization | 64.80K | 65.40K | 64.60K | 50.90K | 42.60K |
| Other Operating Expenses | 110.20K | 108.80K | 56.50K | 145.80K | 75.90K |
| Total Operating Expenses | 10.20M | 11.63M | 9.54M | 10.57M | 8.89M |
| Operating Income | -1.30M | -2.04M | -1.11M | -1.27M | -1.35M |
| Income Before Tax | -1.22M | -2.29M | -982.60K | -838.00K | -1.26M |
| Income Tax Expenses | -40.20K | -128.70K | 215.20K | -343.70K | 22.40K |
| Earnings from Continuing Operations | -1.18M | -2.16M | -1.20M | -494.30K | -1.28M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.18M | -2.16M | -1.20M | -494.30K | -1.28M |
| EBIT | -1.30M | -2.04M | -1.11M | -1.27M | -1.35M |
| EBITDA | -1.23M | -1.97M | -1.04M | -1.22M | -1.31M |
| EPS Basic | -0.44 | -1.00 | -0.95 | -9.94 | -2.00 |
| Normalized Basic EPS | -0.28 | -0.66 | -0.48 | -10.53 | -1.23 |
| EPS Diluted | -0.44 | -1.00 | -0.95 | -9.94 | -2.00 |
| Normalized Diluted EPS | -0.28 | -0.66 | -0.48 | -10.53 | -1.23 |
| Average Basic Shares Outstanding | 2.70M | 2.15M | 1.27M | 49.70K | 641.30K |
| Average Diluted Shares Outstanding | 2.70M | 2.15M | 1.27M | 49.70K | 641.30K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |